Advanced Biomedical Technologies, Inc. (ABMT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Advanced Biomedical Technologies, Inc. (ABMT) with AI Score 68/100 (Buy). Advanced Biomedical Technologies, Inc. is a development stage company focused on designing, developing, manufacturing, and marketing biomaterial internal fixation devices. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Advanced Biomedical Technologies, Inc. (ABMT) Healthcare & Pipeline Overview
Advanced Biomedical Technologies, Inc. is a development stage company specializing in biomaterial internal fixation devices, including surgical screws and binding wires, targeting orthopedic trauma and reconstructive dental procedures. With a negative P/E ratio and high gross margin, ABMT operates in the competitive medical device sector, facing challenges in achieving profitability and scaling production.
Investment Thesis
Advanced Biomedical Technologies, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on polymer osteosynthesis devices for orthopedic and dental applications addresses a significant market need. However, as a development stage company with a negative P/E ratio of -0.05 and a negative profit margin of -190.2%, ABMT's financial viability is a major concern. Key value drivers include successful product development, regulatory approvals, and market adoption of its devices. Growth catalysts include expanding its product line and entering new geographic markets. Potential risks include competition from established medical device companies, challenges in securing funding, and the uncertainty of regulatory approvals. Investors should carefully consider the company's financial position and the inherent risks associated with development stage companies before investing. The company's high Beta of 1.46 suggests higher volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 81.9% indicates strong potential profitability if sales volume increases.
- Negative P/E Ratio of -0.05 reflects the company's current lack of profitability.
- Profit Margin of -190.2% highlights significant operational challenges and high expenses relative to revenue.
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
- Beta of 1.46 suggests the stock is more volatile than the market.
Competitors & Peers
Strengths
- Proprietary biomaterial technology.
- Focus on a specific niche market.
- Potential for high gross margins.
- Experienced management team.
Weaknesses
- Development stage company with limited revenue.
- Negative profitability and cash flow.
- Small size and limited resources.
- Dependence on regulatory approvals.
Catalysts
- Upcoming: Potential FDA approval for new biomaterial internal fixation devices.
- Ongoing: Research and development efforts to expand product line.
- Ongoing: Strategic partnerships with hospitals and clinics to increase market reach.
Risks
- Potential: Competition from established medical device companies.
- Potential: Challenges in securing funding for ongoing operations.
- Potential: Uncertainty of regulatory approvals.
- Ongoing: Negative profitability and cash flow.
- Ongoing: Limited financial disclosure due to OTC listing.
Growth Opportunities
- Expansion into New Therapeutic Areas: ABMT can explore opportunities to expand its product offerings into adjacent therapeutic areas within orthopedics and reconstructive surgery. For example, the company could develop devices for spinal fusion or joint replacement. The global market for spinal implants is projected to reach $12.5 billion by 2028, presenting a significant growth opportunity for ABMT. Timeline: 2-3 years.
- Geographic Expansion: ABMT can pursue geographic expansion into international markets, particularly in emerging economies where there is a growing demand for advanced medical devices. The Asia-Pacific region is expected to be the fastest-growing market for medical devices, driven by increasing healthcare spending and a growing aging population. Timeline: 3-5 years.
- Strategic Partnerships: ABMT can form strategic partnerships with hospitals, clinics, and distributors to expand its market reach and accelerate product adoption. Collaborating with key opinion leaders and academic institutions can also help to validate the company's technology and enhance its credibility. Timeline: 1-2 years.
- Product Innovation: ABMT can invest in research and development to develop innovative biomaterial internal fixation devices with improved performance, biocompatibility, and ease of use. The company can also explore the use of advanced manufacturing techniques, such as 3D printing, to create customized implants tailored to individual patient needs. Timeline: Ongoing.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is crucial for ABMT to commercialize its products and gain market access. The company should prioritize regulatory compliance and invest in the necessary resources to navigate the regulatory approval process efficiently. Timeline: Ongoing.
Opportunities
- Expansion into new therapeutic areas.
- Geographic expansion into emerging markets.
- Strategic partnerships with hospitals and distributors.
- Increasing demand for minimally invasive surgical procedures.
Threats
- Competition from larger, more established medical device companies.
- Technological obsolescence.
- Changes in regulatory requirements.
- Product liability claims.
Competitive Advantages
- Proprietary biomaterial formulations.
- Specialized expertise in polymer osteosynthesis.
- Focus on niche applications in orthopedic and dental surgery.
- Established relationships with key opinion leaders in the medical field.
About ABMT
Founded in 2002 and rebranded in 2009 from Geostar Mineral Corporation, Advanced Biomedical Technologies, Inc. (ABMT) is a development stage company focused on the design, development, manufacturing, and marketing of biomaterial internal fixation devices. The company's core offerings include polymer osteosynthesis devices such as surgical screws, binding wires, and rods, along with related medical devices. These products are intended for use in the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, reconstructive dental procedures, and related treatments. Based in New York City, ABMT aims to provide innovative solutions in the medical device field, particularly in the area of internal fixation. As a development stage company, ABMT is likely focused on research and development, clinical trials, and securing regulatory approvals for its products. The company's success will depend on its ability to effectively commercialize its products and gain market share in a competitive landscape. With a relatively small team of 17 employees, ABMT faces the challenges of scaling its operations and competing with larger, more established players in the medical device industry.
What They Do
- Designs biomaterial internal fixation devices.
- Develops polymer osteosynthesis devices.
- Manufactures surgical screws and binding wires.
- Markets medical devices for orthopedic trauma.
- Offers solutions for sports-related medical treatment.
- Provides devices for cartilage repair.
- Creates products for reconstructive dental procedures.
Business Model
- Develops and manufactures biomaterial-based medical devices.
- Sells products directly to hospitals and clinics.
- Distributes products through a network of distributors.
- Generates revenue from the sale of surgical screws, binding wires, and related devices.
Industry Context
Advanced Biomedical Technologies, Inc. operates in the medical device industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for internal fixation devices is driven by the increasing prevalence of orthopedic trauma, sports-related injuries, and the growing demand for reconstructive dental procedures. ABMT faces competition from established medical device companies with greater resources and broader product portfolios. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively commercialize its technologies in a dynamic and competitive market.
Key Customers
- Hospitals and surgical centers.
- Orthopedic surgeons.
- Dental surgeons.
- Sports medicine clinics.
Financials
Chart & Info
Advanced Biomedical Technologies, Inc. (ABMT) stock price: Price data unavailable
Latest News
No recent news available for ABMT.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABMT.
Price Targets
Wall Street price target analysis for ABMT.
MoonshotScore
What does this score mean?
The MoonshotScore rates ABMT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hui Wang
CEO
Hui Wang is the CEO of Advanced Biomedical Technologies, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing its operations. With a team of 17 employees, Wang is responsible for driving innovation, securing funding, and navigating the regulatory landscape. His background likely includes experience in the medical device industry, with a focus on biomaterials and orthopedic applications.
Track Record: As CEO, Hui Wang's track record is closely tied to the progress of Advanced Biomedical Technologies, Inc. Key milestones under his leadership include the development and commercialization of the company's polymer osteosynthesis devices. His strategic decisions have shaped the company's focus on orthopedic trauma, sports-related medical treatment, and reconstructive dental procedures. However, the company's financial performance, as indicated by its negative P/E ratio and profit margin, presents ongoing challenges.
ABMT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Advanced Biomedical Technologies, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Higher risk of fraud and manipulation.
- Lack of regulatory oversight.
- Going concern risk.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Company has been in operation since 2002.
- Focus on developing and manufacturing medical devices.
- Products target specific medical applications.
- Presence of a CEO and management team.
- Company headquarters located in New York City.
Common Questions About ABMT
What does Advanced Biomedical Technologies, Inc. do?
Advanced Biomedical Technologies, Inc. is a development stage company that designs, develops, manufactures, and markets biomaterial internal fixation devices. These devices, including surgical screws, binding wires, and rods, are primarily used in orthopedic trauma, sports-related injuries, cartilage repair, and reconstructive dental procedures. The company focuses on polymer osteosynthesis devices and aims to provide innovative solutions in the medical device field. As a development stage company, ABMT is currently working to commercialize its products and gain market share.
What do analysts say about ABMT stock?
As of March 16, 2026, there is no readily available analyst coverage for Advanced Biomedical Technologies, Inc. due to its status as an OTC-listed, development stage company. Key valuation metrics such as P/E ratio (-0.05) and profit margin (-190.2%) indicate that the company is not currently profitable. Investors should carefully consider the risks and uncertainties associated with investing in micro-cap, OTC-listed companies before making any investment decisions. Further research and due diligence are recommended to assess the company's potential for future growth and profitability.
What are the main risks for ABMT?
Advanced Biomedical Technologies, Inc. faces several significant risks. As a development stage company, it has limited revenue and negative profitability, making it reliant on securing additional funding. Competition from larger, more established medical device companies poses a threat to its market share. The company's products are subject to regulatory approvals, which can be lengthy and uncertain. Furthermore, as an OTC-listed company, ABMT faces risks related to limited financial disclosure and lower liquidity, increasing the potential for price volatility and manipulation.
What are the key factors to evaluate for ABMT?
Advanced Biomedical Technologies, Inc. (ABMT) currently holds an AI score of 68/100, indicating moderate score. Key strength: Proprietary biomaterial technology.. Primary risk to monitor: Potential: Competition from established medical device companies.. This is not financial advice.
How frequently does ABMT data refresh on this page?
ABMT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ABMT's recent stock price performance?
Recent price movement in Advanced Biomedical Technologies, Inc. (ABMT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary biomaterial technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ABMT overvalued or undervalued right now?
Determining whether Advanced Biomedical Technologies, Inc. (ABMT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ABMT?
Before investing in Advanced Biomedical Technologies, Inc. (ABMT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be up-to-date.